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Abstract
Background: Apolipoprotein E (apoE) induces the uptake of vitamin K-rich lipoproteins by the liver, which likely
affects inter-individual variation of warfarin dosing requirements. Associations between APOE polymorphisms and
warfarin dosing were previously reported inconsistently among different ethnic groups, so the present study
investigated this association in northern Han Chinese patients with mechanical heart valve prosthesis.
Methods: A total of 186 patients who underwent mechanical heart valve replacement and attained a stable
warfarin dose were included. APOE single nucleotide polymorphisms (SNPs) rs7412 and rs429358 were genotyped
using Illumina SNP GoldenGate Assay. Genotyping results were confirmed by direct sequencing. PHASE v2.1
software was used to construct rs7412 and rs429358 haplotypes. The effects of different APOE genotypes on
warfarin dose were analyzed statistically.
Results: The mean warfarin maintenance dose was 3.10 ± 0.96 mg/day, and the mean international normalized
ratio (INR) was 2.09 ± 0.24. APOE E2, E3, and E4 allele frequencies were 11.6 %, 82.5 %, and 5.9 %, respectively. No
E2/E2 or E4/E4 genotypes were detected in this population. E2/E3, E3/E3, E2/E4, and E3/E4 genotype frequencies
were 21.0 %, 67.2 %, 2.2 %, and 9.7 %, respectively. Significant differences in warfarin dose requirements were
observed among patients with E2/E3, E3/E3, and E3/E4 genotypes (p < 0.05). In post hoc comparison, daily warfarin
maintenance doses were significantly higher in E2/E3 heterozygotes compared with E3/E3 homozygotes (p < 0.05),
but no differences in dose requirements were found between E3/E4 and E3/E3, or E2/E3 and E3/E4 (p > 0.05).
Patients were divided into low-intensity anticoagulant treatment group (1.6 ≤ INR <2.0) and relatively high-intensity
anticoagulant treatment group (2.0 ≤ INR ≤2.5), and significantly higher warfarin dose requirements were observed
in E2/E3 heterozygotes compared with E3/E3 homozygotes in both subgroups (p < 0.05). Multivariable analysis
adjusting for other confounders showed that E2/E3 genotype was associated with a significantly higher warfarin
dose compared with E3/E3 genotype (p < 0.05).
Conclusions: APOE allele and genotype frequencies in the northern Han Chinese population appear to differ from
other racial groups or populations living in other regions of China. The APOE E2 variant was associated with a
significantly higher warfarin maintenance dose. Thus, APOE polymorphisms could be one of the predictors
influencing warfarin doses in this population.
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Background
Thromboembolisms, especially cerebral embolisms, are a
common complication of many cardiovascular and cere-
brovascular diseases such as atrial fibrillation, heart valve
prosthesis, deep venous thrombosis, and stroke. Warfarin
is the most highly prescribed oral anticoagulant for the
treatment and prevention of thromboembolism in clinical
practice. However, because of its narrow therapeutic index
and the wide variability in drug response among individ-
uals, its use is reported to be the most common adverse
drug event, accounting for approximately one third of
emergency hospitalizations for the elderly [1, 2]. Thus,
prescribing the correct dosage of warfarin is directly re-
lated to the prognosis of many cardiovascular and cere-
brovascular diseases.
Several studies have shown that genetic polymorphisms
are the main factor responsible for inter-individual variabil-
ity in warfarin response. Because of this, the US Food and
Drug Administration revised the drug instructions in 2007
and 2010 to incorporate genetic information about
VKORC1 and CYP2C9 to guide the clinical medication of
warfarin [3]. The International Warfarin Pharmacogenetics
Consortium also explicated a pharmacogenetic model in-
corporating VKORC1, CYP2C9, and nongenetic factors
such as age, height, weight, and the combination use of
amiodarone to predict warfarin dose in clinical practice [4].
However, this pharmacogenetic algorithm and others can
only explain approximately 50 % of warfarin dose variation
[5–7], indicating that additional genetic polymorphisms
may be involved in affecting warfarin dosing requirements.
Apolipoprotein E (APOE) is an essential component of
lipoproteins that is involved in lipid transportation and in-
duces the uptake of lipoproteins rich in vitamin K1 by the
liver [8]. Because warfarin exerts its anticoagulant effects
by preventing oxidized vitamin K from regenerating re-
duced vitamin K in the liver, warfarin dose requirements
are likely to be influenced by the availability of hepatic
vitamin K. Human Apoe, situated on chromosome 19, ex-
ists in three common allelic forms: E2, E3, and E4, giving
six possible genotypes (E2/E2, E2/E3, E2/E4, E3/E3, E3/
E4, and E4/E4) [9–11]. In previous studies, associations
between APOE polymorphisms and warfarin dosing were
reported inconsistently among different ethnic groups.
Given that the northern Han Chinese population differs in
terms of lifestyle, culture, and dietary habits from those in
other regions of China, it is meaningful to investigate the
potential association between APOE polymorphisms and
warfarin dosing in northern Han Chinese patients with
mechanical heart valve prosthesis.
Results
Characteristics of the study population
Demographic and clinical characteristics of patients
(n = 186) are shown in Table 1. Smoking, drinking, as
well as BSA, weight, height, blood urea nitrogen
(BUN), and serum creatinine (SCR) showed significant
differences between males and females (p < 0.05), but no
difference was found among other variables (p > 0.05).
Genotyping
As shown in Fig. 1, genotyping results for rs7412 and
rs429358 were confirmed by direct sequencing. PHASE
v2.1 software was used to construct haplotypes of APOE
single nucleotide polymorphisms (SNPs) rs7412 and
rs429358. Haplotype TT was coded as E2, TC as E3, and
CC as E4 alleles. E2, E3, and E4 allele frequencies were
Table 1 Comparison of demographic and clinical characteristics
in terms of gender
Variable Males Females P-value
Age (years) 54.95±11.15 56.42±9.08 0.328
Smoking (n, %) 8(8.6) 0(0) 0.004
Drinking (n, %) 8(8.6) 0(0) 0.004
BSA (m2) 1.78±0.16 1.61±0.13 <0.001
BMI (kg/ m2) 24.20±3.18 24.01±3.27 0.686
Weight (kg) 70.12±10.81 61.43±9.14 <0.001
Height (cm) 170.08±5.61 159.89±5.15 <0.001
Hypertension (n, %) 21(22.6) 12(12.9) 0.084
Hyperlipidemia (n, %) 10(10.8) 8(8.6) 0.620
Diabetes (n, %) 7(7.5) 11(11.8) 0.321
CAD (n, %) 9(9.7) 8(8.6) 0.799
Stroke (n, %) 4(4.3) 4(4.3) 1.000
SBP (mm Hg)* 125 (120–130) 125 (116.5–130) 0.990
DBP (mm Hg)* 74 (64–80) 74 (64–80) 0.737
Triglycerides (mmol/L)* 1.31 (0.86–2.05) 1.30 (0.99–1.87) 0.540
Total cholesterol (mmol/L) 4.72±1.02 4.81±1.13 0.566
LDL-C (mmol/L) 2.92±0.86 2.96±0.91 0.782
HDL-C (mmol/L) 1.11±0.31 1.15±0.32 0.342
FBG (mmol/L)* 5.28 (4.91–5.74) 5.40 (4.97–5.91) 0.398
CRP (mg/L)* 1.01 (0.47–3.35) 1.11 (0.59–3.47) 0.638
BUN (mmol/L)* 6.70 (5.80–7.85) 5.50 (4.70–6.70) <0.001
SCR (umol/L) 83.25±13.60 69.71±19.93 <0.001
eGFR (ml/min/1.73m2) 94.67±16.52 89.78±19.39 0.066
Amiodarone use (n, %) 2(2.2) 4(4.3) 0.678
Diltiazem use (n, %) 1(1.1) 4(4.3) 0.365
Statins use (n, %) 8(8.6) 5(5.4) 0.388
Dioxin use (n, %) 17(18.3) 16(17.2) 0.848
Insulin use (n, %) 4(4.3) 5(5.4) 0.733
*Continuous variables with skewed distribution were reported as medians (Q1
and Q3); BSA: body surface area; BMI: body mass index; CAD: coronary artery
disease; SBP: systolic blood pressure; DBP: diastolic blood pressure; HDL-C:
high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol;
FBG: fasting blood glucose; CRP: C-reactive protein; BUN: blood urea nitrogen;
SCR: serum creatinine; eGFR: glomerular filtration rate
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11.6 %, 82.5 %, and 5.9 %, respectively. As shown in
Table 2, we observed a difference between our data from
the northern Han Chinese population and those from
previous studies of other ethnic groups. The observed
genotype frequency showed no deviation from Hardy–
Weinberg equilibrium (HWE; χ2 = 4.342, p = 0.227).
Effect of APOE polymorphisms on warfarin maintenance
dose
The stable warfarin dose and INR values of patients with
different APOE genotypes are shown in Table 3. Mean
stable warfarin dose requirements were 3.10 ± 0.96 mg/
day (range, 0.75–7.5 mg/day), with a coefficient of
variance of 30.97 %. Significant differences in warfarin
dose requirements were observed among carriers of E2/
E3, E3/E3, and E3/E4 genotypes (p < 0.05). In the post
hoc pairwise comparison, warfarin dose requirements
were significantly higher in patients with the E2/E3
genotype compared with those with the E3/E3 genotype
(p < 0.05), but no differences were found between car-
riers of E3/E4 and E3/E3, or E2/E3 and E3/E4 genotypes
(p > 0.05). In addition, the mean INR values were 2.09 ±
0.24, but there was no significant difference in INR
values among the three APOE genotypes (p > 0.05).
Considering that patients with different heart valve
prostheses require different treatment goals, we
Fig. 1 Sequence of APOE rs7412 (CC, CT) and rs429358 (TT, TC) genotypes (5’-3’), the arrow showed the mutation. (a: rs7412 CC, b: rs7412 CT, c:
rs429358 TT, d: rs429358 TC)
















APOE E2 43(11.6) E2/E2 0(0) 3(1.20) 0(0) 3(2.7) 3(1.54) 1(0.8)
E3 307(82.5) E2/E3 39(21) 39(15.66) 16(13.22) 15(13.51) 20(10.26) 17(14.7)
E4 22(5.9) E2/E4 4(2.2) 2(0.80) 3(2.48) 7(6.31) 3(1.54) 2(1.7)
E3/E3 125(67.2) 180(72.29) 73(60.33) 51(45.95) 146(74.87) 66(56.9)
E3/E4 18(9.7) 23(9.24) 28(23.14) 30(27.03) 23(11.79) 26(22.5)
E4/E4 0(0) 2(0.80) 1(0.83) 5(4.50) 0(0) 4(3.4)
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divided patients into low-intensity anticoagulant treat-
ment group (1.6 ≤ INR <2.0) and relatively high-
intensity anticoagulant treatment group (2.0 ≤ INR ≤
2.5) based on measured INR values. As shown in
Fig. 2, stable warfarin dose requirements were signifi-
cantly higher in E2/E3 heterozygotes compared with
E3/E3 homozygotes in both subgroups (both p < 0.05).
After adjusting for other variables (sex, age, BSA,
BMI, eGFR categories, smoking and drinking status,
coronary artery disease, hyperlipidemia, hypertension,
diabetes, stroke history, measured INR and number of
concomitant medications that increase INR values) in
a multivariable analysis, E2/E3 genotype was associ-
ated with a statistically higher warfarin dose com-
pared with E3/E3 genotype (p < 0.05). Besides, BSA
was associated with a significantly higher warfarin
dose (p < 0.05) while increased age and number of
concomitant medications that increased INR values
were associated with a significantly lower warfarin
dose (p < 0.05) (Table 4).
Discussion
In the present study, we demonstrated APOE E2, E3,
and E4 allele frequencies in the northern Han Chinese
population of 11.6 %, 82.5 %, and 5.9 %, respectively,
which differs from data of other ethnic groups. The al-
lele frequency of E2 (11.6 %) in this study was higher
than the results reported by Huang et al [12] derived
from the southwest Chinese population. The E4 allele
frequency (5.9 %) was similar to that reported by Huang
et al, but lower than that of other ethnic groups, which
ranged from 13.64 % to 21.17 % [13, 14]. Significant dif-
ferences in warfarin dose requirements were observed
among carriers of E2/E3, E3/E3, and E3/E4 genotypes.
In post hoc comparison, E2/E3 heterozygotes required a
16.1 % higher daily warfarin dose than E3/E3 homozy-
gotes. No differences in dose requirements were found
between carriers of E3/E4 and E3/E3, or E3/E4 and E2/
E3 genotypes. Based on differences in measured INR
values, we divided patients into low-intensity warfarin
treatment group (1.6 ≤ INR <2.0) and relative high-
Table 3 Daily warfarin maintenance dose and INR values of different APOE genotypes
APOE genotype Patient Number Mean ± SDINR valueb Mean ± SDwarfarindose (mg/d) P value
E2/E3 (E2 carriera) 39 2.06±0.25 3.47±1.04 0.024
E3/E3 125 2.10±0.24 2.99±0.93
E3/E4 (E4 carriera) 18 2.11±0.21 2.97±0.82
E2/E3 vs E3/E3 0.007
E2/E3 vs E3/E4 0.080
E3/E3 vs E3/E4 0.993
aPatients (n=4) with the E2/E4 genotype were excluded from analysis
bp=0.511 (compared among three genotypes)
Fig. 2 Comparison of daily stable warfarin dose requirements between E2/E3 heterozygotes and E3/E3 homozygotes in two subgroups based on
patient INR values. (a) low-intensity anticoagulant treatment group: 1.6≤ INR <2.0; (b) relatively high-intensity anticoagulant treatment group:
2.0≤ INR ≤2.5, * p < 0.05, analyzed by independent t-tests
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intensity warfarin treatment group (2.0 ≤ INR ≤2.5).
Significantly higher warfarin dose requirements were ob-
served in E2/E3 heterozygotes compared with E3/E3
homozygotes in both subgroups (p < 0.05). In a multivar-
iable analysis adjusting for other demographic and clin-
ical variables such as age, sex, BSA, eGFR categories and
number of concomitant medications that potentiate
warfarin, E2/E3 genotype was associated with a signifi-
cantly higher warfarin does compared with E3/E3 geno-
type (p < 0.05). To our knowledge, this is the first report
linking APOE polymorphisms with the warfarin dosage
in a Chinese population.
To date, the effect of APOE polymorphisms on the
anticoagulant response and dose requirements of war-
farin have been reported inconsistently. APOE induces
the uptake of vitamin K-rich lipoproteins by the liver.
Changes in vitamin K content in the body can signifi-
cantly affect warfarin anticoagulation activity and dose
requirements, but the mechanism by which APOE poly-
morphisms acts on liver vitamin K availability has been
poorly elucidated. Because different APOE isoforms ex-
hibit different affinities to remnant and LDL receptors,
the hepatic clearance of vitamin K-rich chylomicron
remnants varies between APOE isoforms and is in the
order of E2 < E3 < E4. Thus, it has therefore been hy-
pothesized that the E2 variant mediates a relatively low
uptake of vitamin K by the liver, inhibiting the hepatic
availability of vitamin K for the carboxylation of clotting
factors. Thus, apoE2 carriers theoretically require less
warfarin to achieve adequate anticoagulation effects.
However, in a contrasting hypothesis, E3 and E4 variants
exhibit an accelerated clearance of vitamin K-rich chylo-
microns from the blood compared with the E2 variant.
This implies an accelerated uptake of vitamin K by the
liver. However, most accelerated vitamin K in the liver
bypasses the intracellular vitamin-K dependent synthesis
of active coagulation factors, but facilitates the more
extensive metabolism and excretion and is directly elimi-
nated. As a consequence, E3 and E4 variants lead to a
decreased hepatic availability of vitamin K, so apoE3 or
apoE4 carriers require less warfarin than apoE2 carriers.
Our results support the latter hypothesis.
Our results are similar to those of Huang et al. [12] from
a southwest Han Chinese population, which indicated that
patients carrying the E2 allele required a higher warfarin
maintenance dose. Sconce et al. [8] also reported similar
results from a Caucasian population. However, both of
these studies failed to show a statistically significant differ-
ence, unlike our present findings. Besides, Sconce et al.
showed that patients carrying at least one E4 allele re-
quired a lower warfarin maintenance dose than those car-
rying the E3/E3 genotype (p < 0.05). Results from de
Oliveira et al. [14] in Brazilian patients also demonstrated
that patients carrying at least one E4 allele required a
lower warfarin dosage. By contrast, Kohnke et al. studied a
Swedish population [15] and suggested that E4 carriers
(E2/E4, E3/E4, and E4/E4 genotypes) have enhanced liver
uptake of vitamin K and require a higher warfarin dosage
to compensate for this. Our study found that patients
carrying the E4 allele showed no significant difference
in dose requirements from E3/E3 or E2/E3 genotype
carriers. This is likely due to the fact that the E4
allele frequency is much lower in the Chinese popula-
tion compared with other ethnic groups. Because only
18 patients carrying the E3/E4 genotype were de-
tected in the present study, it was difficult to estab-
lish whether the APOE E4 variant influenced warfarin
maintenance dose in the northern Han Chinese
population.
The present study has a number of limitations. First,
we did not measure plasma vitamin K concentrations,
yet different concentrations may reflect the delivery effi-
cacy of vitamin K-rich remnants to the liver in different
APOE isoforms. Second, our study was restricted by its
relatively small sample size; in particular, only 18 pa-
tients had the E3/E4 genotype and no E2 or E4 homozy-
gotes were detected. Finally, because we recruited
patients with heart valve prosthesis from the northern
China, our results may not be able to be directly gener-
alized to other populations.
Table 4 Multivariable models for APOE polymorphisms using square root transformed warfarin dose
Variables Beta Coefficients P-value
Intercept 1.515
Age (per year increase) -0.006 0.002
Body surface area 0.325 0.005
E2/E3 genotype* 0.113 0.020
E3/E4 genotype* -0.018 0.782
Number of concomitant medications that increase INR values† -0.130 0.035
*We set the E3/E3 genotype as a reference, and regarded E2/E3 and E3/E4 genotype as dummy variables in the multivariable analysis. †Concomitant medications
included amiodarone, diltiazem, fluvastatin, simvastatin and lovastatin
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Conclusions
APOE allele and genotype frequencies in the northern
Han Chinese population differ from those of other racial
groups and populations living in other regions of China.
APOE E2/E3 genotype was associated with a significantly
higher warfarin maintenance dose compared with E3/E3
genotype. Thus, APOE polymorphisms appear to be one
of the predictors influencing warfarin dose in the north-
ern Han Chinese population. The effect of APOE poly-
morphisms on warfarin dosage was relatively small, thus
consideration of the APOE genotype in isolation is un-
likely to be of clinical relevance. Whereas, if rapid and
cost-effective genotyping technologies were available in
the future, it would be feasible to test APOE genotypes, to-
gether with VKORC1, CYP2C9 and other nongenetic fac-
tors, to help better predict warfarin dose requirements.
Methods
Subjects
Between April 2012 and May 2015, 226 ethnic Han Chinese
inpatients undergoing mechanical heart valve replacement
were recruited from the Cardiac Surgery Department of
Anzhen Hospital, Capital Medical University (Beijing,
China). Our inclusion criteria were that patients had to be
Han Chinese and lived in northern China (Beijing,
Shandong, Shanxi, Henan, Hebei, Heilongjiang, Jilin,
Liaoning, and Inner Mongolia provinces); at least 18 years
old; able to provide written consent; under warfarin antic-
oagulation for more than 3 months and had attained a
stable maintenance dose. A stable warfarin maintenance
dose was defined as administration of a constant dose for at
least 1 month with international normalized ratio (INR)
measurements within the target range for multiple time pe-
riods after discharge. The target ranges were 1.6–2.0 for
aortic valve replacement, 1.8–2.5 for mitral valve replace-
ment, and 1.8–2.5 for double valve replacement. This rela-
tively low target INR was chosen because Asian patients
are more sensitive to warfarin therapy so are more likely to
suffer episodes of bleeding than Caucasians [16].
Thus, the majority of Chinese patients are suitable for
low intensity anticoagulation with a target INR lower
than 2–3. Compared with standard intensity anticoa-
gulation, this lower intensity is equally effective at
preventing thrombotic events, and more likely to de-
crease bleeding during treatment [17–20].
Our exclusion criteria were as follows: (1) hematological
disease or hemorrhagic tendencies; (2) blood platelet
count <120 × 109/L; (3) heart failure (New York Heart As-
sociation class 3 or class 4); (4) liver dysfunction (defined
as the presence of chronic hepatic disease or biochemical
evidence of significant hepatic impairments); (5) renal dys-
function (defined as chronic dialysis or serum creatinine
>200 mM or recipient of kidney transplantation); (6) thy-
roid disease; (7) malignant tumors; (8) peptic ulcers; (9)
infections; (10) autoimmune disease; and (11) pregnancy.
This study was carried out in accordance with the Declar-
ation of Helsinki Principles and approved by the Ethics
Committee of Beijing Anzhen Hospital, Capital Medical
University. All subjects provided written informed consent
to participate in the study.
The patients were followed up after surgery until
August 2015, and the follow-up period ranged from 4 to
35 months. During follow-up, 17 patients who did not
meet the criteria were excluded from study. 17 patients
refused to participate after enrollment. One patient died
of unexplained heart failure. Three patients lost to follow
up. Another two patients who were unsuccessfully geno-
typed were also excluded from study. Thus, a total of
186 patients with complete genetic and clinical informa-
tion were included in subsequent analysis.
Clinical data
We collected patient clinical data by means of regular
telephone calls, face-to-face interviews, and a review of
medical records from our hospital information system.
These data included age, gender, age at the time of oper-
ation, height, weight, indication for warfarin treatment,
valve position, valve types, routine INR values, stable
warfarin dose, concomitant disease, concurrent interact-
ing medications, current smoking status, and alcohol
consumption. Body surface area (BSA) was defined as:
0.0061 × height (cm) + 0.0128 × weight (kg) – 0.1529
[21], and body mass index (BMI) as: weight (kg)/ [height
(m)2]. Glomerular filtration rate (eGFR) was estimated
using the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) equation [22] and grouped
patients into the KDIGO (Kidney Disease: Improving
Global Outcomes) eGFR categories [23]: ≥90, 60–89
and 45–59 ml/min/1.73 m2. Hyperlipidemia was diag-
nosed with an elevation of at least one of the follow-
ing: >6.22 mmol/L for total cholesterol, >2.26 mmol/L
for triglycerides, or >4.14 mmol/L for low-density
lipoprotein cholesterol (LDL-C); hypertension was di-
agnosed after taking a mean of three independent
measures of blood pressure >140/90 mmHg; and
diabetes mellitus was diagnosed if the patient had a
fasting glucose >7.0 mmol/L, or >11.1 mmol/L 2 h
after an oral glucose challenge, or both. Smokers were
self-reported as using cigarettes every day and having
smoked in the past 30 days before follow-up; drinkers
of alcohol were defined as those consuming a daily
average of ≥15 g pure alcohol for females or ≥25 g
for males during the past year.
Biochemical parameters
Blood samples were drawn from each patient under
morning fasting conditions. Triglycerides (TG), serum
total cholesterol (TC), low density lipoprotein cholesterol
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(LDL-C), high density lipoprotein cholesterol (HDL-C),
fasting blood glucose (FBG), blood urea nitrogen (BUN),
serum creatinine (SCR) and other biochemical parameters
were determined at the clinical laboratory of Beijing
Anzhen Hospital, Capital Medical University.
DNA extraction
Blood samples were taken from eligible patients for
genotyping before they underwent surgery. A total of
5 ml venous blood from each patient was collected in
an EDTA vacuum tube and stored at 4 °C before
DNA extraction. Genomic DNA was extracted using
the Blood DNA System DNA isolation kit (CWBIO,
Beijing, China) according to the manufacturer’s in-
structions and stored at 4 °C for subsequent use.
DNA quality and purity were assessed by agarose gel
electrophoresis, and optical absorbance was measured
at A260/A280.
SNP beadchip assay
Genotyping was performed using the Illumina SNP
Golden Gate Assay (Illumina, Inc., San Diego, CA) ac-
cording to the manufacturer’s specifications. Briefly,
250 ng of genomic DNA was amplified at 37 °C for 20 h,
then fragmented and precipitated. The dried pellet
was resuspended and hybridized to the beadchip.
Hybridized beadchips were incubated at 48 °C for
20 h, washed, and used for single-base extension.
Beadchips were then stained, washed, coated, and
dried. Finally, signal intensity data were generated by
an Illumina BeadArray Reader. We randomly selected
20 % of all samples to be genotyped in duplicate,
which resulted in 99.8 % concordance. Inconsistent
data were excluded from the final analysis.
Sequencing
Ten of APOE rs7412 CC type, CT type and rs429358
TT type, TC type were randomly selected for sequen-
cing, respectively. Primers were designed using Primer
premier 5.0 software and were synthesized by Beijing
Sunbiotech Biological Engineering Co., Ltd. The primers
sequence was shown in Table 5. PCR amplification was
performed in C1000TM Thermal Cycler PCR instru-
ment. 30 μl of PCR reaction system contained 15 μl of
PCR Master mix (2×), 2.4ul of upstream and down-
stream primers (10pmol/ul), 11.4 μl of ddH2O, and
1.2 μl of genomic DNA. Cycling parameters were as fol-
lows: 95 °C denaturation for 3 min, 94 °C deformation
for 30 s, 62 °C annealing for 35 s, 72 °C extension for
40s, a total of 35 cycles were include, total extension at
72 °C for 5 min. After amplification, the PCR products
were detected by 1.5 % agarose gel electrophoresis.
Direct sequencing by Beijing Sunbiotech Biological
Engineering Co., Ltd. was performed to confirm these
genotypes.
Statistical analysis
Continuous variables with a normal distribution were re-
ported as means ± standard deviation (SD) and tested by
an independent samples t-test; continuous variables with
a skewed distribution were reported as medians (Q1 and
Q3) and tested by the Kolmogorov–Smirnov test; cat-
egorical variables were reported as counts (frequencies)
and tested by a two-sided chi-square test. The HWE test
was conducted to assess whether genotype frequencies
were in conformity with predictions based on allele fre-
quencies. PHASE v2.1 software was used to construct
haplotypes of APOE SNPs rs429358 and rs7412.
Warfarin dosage with a skewed distribution was square
root-transformed before analysis. Because the E2/E4
genotype is rare, while E2 and E4 alleles have a recipro-
cal influence on warfarin dose requirements, the four
patients with an E2/E4 genotype were excluded from
subsequent analysis. Differences in the daily mainten-
ance dose of warfarin and INR values in different geno-
type groups were calculated using analysis of variance
with post hoc comparison using least significant differ-
ence analysis. Subsequently patients were divided into
low-intensity anticoagulant treatment group (1.6 ≤ INR
<2.0) and relatively high-intensity anticoagulant treat-
ment group (2.0 ≤ INR ≤2.5) based on measured INR
values. Differences in the daily maintenance dose be-
tween E2/E3 heterozygotes and E3/E3 homozygotes
were calculated using two independent-samples t-tests
in both subgroups. Finally, we considered sex, age, BSA,
BMI, eGFR categories, smoking and drinking status,
coronary artery disease, hyperlipidemia, hypertension, dia-
betes, stroke history, measured INR, number of concomi-
tant medications that increase INR value, together with
APOE genotypes as independent variables in the multivar-
iable regression analysis. For APOE genotypes, we set the
E3/E3 genotype as a reference and regarded E2/E3 and
E3/E4 as dummy variables. A two-tailed probability value
of <0.05 was considered significant. Statistical analyses
were carried out using Statistical Package for Social
Science (SPSS ver.20.0, SPSS Science, Chicago, IL).
Table 5 The loci, primer sequences, annealing temperature and the product length of amplified gene
Gene locus Primer Sequences (5’-3’) Annealing temperature (°C) Product length (bp)
rs7412, rs429358 GGCACGGCTGTCCAAGGAGCCCCGGCCTGGTACAC 62 228
Liu et al. Lipids in Health and Disease  (2016) 15:34 Page 7 of 8
Abbreviations
APOE: apolipoprotein E; SNPs: single nucleotide polymorphisms;
INR: International normalized ratio; BSA: body surface area; BMI: body mass
index; CAD: coronary artery disease; SBP: systolic blood pressure;
DBP: diastolic blood pressure; HDL-C: high-density lipoprotein cholesterol;
LDL-C: low-density lipoprotein cholesterol; FBG: fasting blood glucose;
CRP: C-reactive protein; BUN: blood urea nitrogen; SCR: serum creatinine;
eGFR: glomerular filtration rate; HWE: Hardy–Weinberg equilibrium.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
RL, QZ and ZZG carried out the molecular genetic studies and the statistical
analysis, and RL drafted the manuscript. XDP carried out the genotyping. KZ,
RL and XMS participated in the design of the study. RL and KZ performed
the investigation. RD conceived of the study and participated in its design
and coordination and helped to draft the manuscript. All authors read and
approved the final manuscript.
Acknowledgments
We would like to thank all participants, individuals and institution for
supporting the study. This work was supported by grants from the National
Natural Science Foundation of China (81270300).
Author details
1Cardiac Surgery, Beijing Institute of Heart, Lung and Blood Vessel Disease,
Beijing Anzhen Hospital, Capital Medical University, No. 2 Anzhen Street,
Chaoyang District, Beijing 100029, China. 2Department of Epidemiology,
Beijing Institute of Heart, Lung and Blood Vessel Disease, Beijing Anzhen
Hospital, Capital Medical University, No. 2 Anzhen Street, Chaoyang District,
Beijing 100029, China. 3Division of Cardiology, Department of pediatrics,
Shandong Provincial Hospital Affiliated to Shandong University, Jingwuweiqi
Street, Huaiyin District, Jinan 250000, China. 4Experimental Center, Beijing
Institute of Heart, Lung and Blood Vessel Disease, Beijing Anzhen Hospital,
Capital Medical University, No. 2 Anzhen Street, Chaoyang District, Beijing
100029, China.
Received: 11 October 2015 Accepted: 16 February 2016
References
1. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency
hospitalizations for adverse drug events in older Americans. N Engl J Med.
2011;365:2002–12.
2. Landefeld C, Beyth R. Anticoagulation-related bleeding: clinical
epidemiology, prediction and prevention. Am J Med. 1993;95:315–28.
3. Finkelman BS, Gage BF, Johnson JA, Brensinger CM, Kimmel SE. Genetic
warfarin dosing: tables versus algorithms. J Am Coll Cardiol. 2011;57:612–8.
4. Lee MT, Chen YT, Wen MS, Lee MT, Caraco Y, Achache I, et al. Estimation of
the warfarin dose with clinical and pharmacogenetic data. N Engl J Med.
2009;360:753–64.
5. Chen J, Shao L, Gong L, Luo F, Wang J, Shi Y, et al. A pharmacogenetics-based
warfarin maintenance dosing algorithm from Northern Chinese patients. PLoS
One. 2014. doi:10.1371/journal.pone.0105250.
6. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S, et al.
The largest prospective warfarin-treated cohort supports genetic
forecasting. Blood. 2009;113:784–92.
7. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, et al. Use of
pharmacogenetic and clinical factors to predict the therapeutic dose of
warfarin. Clin Pharmacol Ther. 2008;84:326–31.
8. Sconce EA, Daly AK, Khan TI, Wynne HA, Kamali F. APOE genotype makes a
small contribution to warfarin dose requirements. Pharmacogenet
Genomics. 2006;16:609–11.
9. Zhu S, Wang Z, Wu X, Shu Y, Lu D. Apolipoprotein E polymorphism is
associated with lower extremity deep venous thrombosis: color-flow Doppler
ultrasound evaluation. Lipids Health Dis. 2014. doi:10.1186/1476-511X-13-21.
10. Yu B, Chen W, Wang R, Qi Q, Li K, Zhang W, et al. Association of
apolipoprotein E polymorphism with maximal oxygen uptake after exercise
training: a study of Chinese young adult. Lipids Health Dis. 2014.
doi:10.1186/1476-511X-13-40.
11. Sun YP, Zhang B, Miao L, Wang XM, Yu JH, Luo L, et al. Association of
apolipoprotein E (ApoE) polymorphisms with risk of primary
hyperuricemia in Uygur men, Xinjiang, China. Lipids Health Dis.
2015; doi: 10.1186/s12944-015-0025-2
12. Huang S, Chen B, Xiang D, Huang L, An B, Li G. Association between
apolipoprotein E gene polymorphism and the dose for warfarin
maintenance. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2011;36:212–6.
13. Kimmel SE, Christie J, Kealey C, Chen Z, Price M, Thorn CF, et al.
Apolipoprotein E genotype and warfarin dosing among Caucasians and
African Americans. Pharmacogenomics J. 2008;8:53–60.
14. de Oliveira Almeida VC, Ribeiro DD, Gomes KB, Godard AL. Polymorphisms
of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 genes and the therapeutic
warfarin dose in Brazilian patients with thrombosis: a prospective cohort
study. Mol Diagn Ther. 2014;18:675–83.
15. Kohnke H, Sorlin K, Granath G, Wadelius M. Warfarin dose related to
apolipoprotein E (APOE) genotype. Eur J Clin Pharmacol. 2005;61:381–8.
16. Suzuki S, Yamashita T, Kato T, Fujino T, Sagara K, Sawada H, et al. Incidence
of major bleeding complication of warfarin therapy in Japanese patients
with atrial fibrillation. Circ J. 2007;71:761–5.
17. Dong L, Shi YK, Tian ZP, Ma JY, Wang X, Yi J. Low intensity anticoagulation
therapy after mechanical heart valve replacement. Zhonghua Wai Ke Za Zhi.
2003;41:250–2.
18. Yasaka M, Minematsu K, Yamaguchi T. Optimal intensity of international
normalized ratio in warfarin therapy for secondary prevention of stroke in
patients with non-valvular atrial fibrillation. Intern Med. 2001;40:1183–8.
19. You JH, Chan FW, Wong RS, Cheng G. Is INR between 2.0 and 3.0 the
optimal level for Chinese patients on warfarin therapy for moderate-intensity
anticoagulation? Br J Clin Pharmacol. 2005;59:582–7.
20. Haibo Z, Jinzhong L, Yan L, Xu M. Low-intensity international normalized
ratio (INR) oral anticoagulation therapy in Chinese patients with mechanical
heart valve prostheses. Cell Biochem Biophys. 2012;62:147–51.
21. Stevenson PH. Height-weight-surface formula for the estimation of surface
area in Chinese subjects. Chin J Physiol. 1937;3:327–30.
22. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro III AF, Feldman HI, et al.
A new equation to estimate glomerular filtration rate. Ann Intern Med.
2009;150:604–12.
23. Stevens PE, Levin A, Kidney Disease: Improving Global Outcomes Chronic
Kidney Disease Guideline Development Work Group Members. Evaluation
and management of chronic kidney disease: synopsis of the kidney disease:
improving global outcomes 2012 clinical practice guideline. Ann Intern
Med. 2013;158:825–30.
24. Shahin MH, Khalifa SI, Gong Y, Hammad LN, Sallam MT, El Shafey M, et al.
Genetic and nongenetic factors associated with warfarin dose requirements
in Egyptian patients. Pharmacogenet Genomics. 2011;21:130–5.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Liu et al. Lipids in Health and Disease  (2016) 15:34 Page 8 of 8
